{
  "version": 2,
  "updatedAt": "2025-01-23T00:00:00Z",
  "id": "urinary-genitourinary",
  "name": "Urinary & Genitourinary Infections",
  "description": "UTI, pyelonephritis, prostatitis, and GU infections",
  "icon": "water_drop",
  "color": "#00BCD4",
  "conditions": [
    {
      "id": "uncomplicated-cystitis",
      "name": "Uncomplicated Cystitis",
      "synonyms": ["UTI", "bladder infection", "simple cystitis"],
      "icd10": ["N30.00", "N30.90"],
      "severity": ["mild"],
      "shortDescription": "Acute bacterial infection of the bladder in non-pregnant women without structural/functional urinary tract abnormalities",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "clinical_presentation": "Dysuria, urinary frequency, urgency, suprapubic pain. No fever or flank pain (suggests pyelonephritis).",
            "diagnostic_criteria": "Clinical symptoms + pyuria (≥10 WBC/hpf) or positive urine culture (≥10³ CFU/mL).",
            "red_flags": [
              "Fever >38°C (suggests pyelonephritis)",
              "Flank pain (suggests upper tract involvement)",
              "Pregnancy",
              "Male patient (always considered complicated)",
              "Immunosuppression"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Urinalysis (UA) recommended. Urine culture NOT routinely needed for uncomplicated cystitis in non-pregnant women.",
            "when_not_to_test": "Do NOT culture asymptomatic bacteriuria (except in pregnancy or before urologic procedures)",
            "essential_tests": [
              "Urinalysis (dipstick or microscopy)",
              "Urine culture (if recurrent UTI, treatment failure, or atypical presentation)"
            ],
            "conditional_tests": [
              "Urine culture: If pregnant, male, recurrent UTI, or recent antibiotic use",
              "Renal function tests: If concern for pyelonephritis or AKI"
            ],
            "specimen_collection": "Clean-catch midstream urine. Avoid catheterization unless necessary.",
            "turnaround_time": "UA: 1 hour. Urine culture: 24-48 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (75-95%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Staphylococcus saprophyticus (young women)"
            ],
            "resistance_patterns": "E. coli resistance to ampicillin: 30-50%. TMP-SMX resistance: 15-25% in many regions. Fluoroquinolone resistance: 10-20%.",
            "mdro_risk_factors": [
              "Recent antibiotic use (90 days)",
              "Recent hospitalization",
              "Recurrent UTIs",
              "International travel"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "preferred": "Nitrofurantoin 100mg PO BID x 5 days OR Trimethoprim-sulfamethoxazole DS PO BID x 3 days (if local resistance <20%)",
              "alternative": "Fosfomycin 3g PO single dose"
            },
            "alternatives": "Beta-lactam allergy: Nitrofurantoin or fosfomycin. If TMP-SMX resistance >20%: Use nitrofurantoin or fosfomycin.",
            "avoid_list": "Avoid fluoroquinolones for uncomplicated cystitis (reserve for complicated UTI/pyelonephritis)"
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Continue empiric therapy if susceptible",
              "ESBL_E_coli": "Nitrofurantoin (if susceptible) OR Fosfomycin",
              "Enterococcus": "Amoxicillin 500mg PO TID OR Nitrofurantoin"
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results",
            "iv_to_po_switch": "Not applicable (oral therapy for uncomplicated cystitis)"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "3-5 days for most agents",
            "short_course": "TMP-SMX: 3 days. Nitrofurantoin: 5 days. Fosfomycin: Single dose.",
            "prolonged": "7 days if slow response or risk factors for complicated UTI"
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Avoid nitrofurantoin if CrCl <30 mL/min. Adjust TMP-SMX for CrCl <30 mL/min.",
            "pregnancy": "Preferred: Amoxicillin-clavulanate, cephalexin, nitrofurantoin (avoid in 3rd trimester). Avoid: TMP-SMX (1st trimester), fluoroquinolones.",
            "recurrent_uti": "Consider prophylaxis (nitrofurantoin 50-100mg daily, TMP-SMX SS daily, or post-coital dosing)"
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "avoid_unnecessary_cultures": "Do NOT culture asymptomatic bacteriuria (except pregnancy or pre-procedure)",
            "timeout_checklist": [
              "Reassess at 48-72 hours if symptoms not improving",
              "Review culture results if obtained",
              "Avoid prolonged therapy (>5-7 days) unless complicated"
            ],
            "iv_to_po_opportunities": "Not applicable (oral therapy for uncomplicated cystitis)"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Uncomplicated Cystitis Guidelines (2010, reaffirmed 2019)",
              "url": "https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-in-women/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "EAU Guidelines on Urological Infections (2024)",
              "url": "https://uroweb.org/guidelines/urological-infections"
            }
          ]
        }
      }
    },
    {
      "id": "pyelonephritis",
      "name": "Acute Pyelonephritis",
      "synonyms": ["kidney infection", "upper UTI"],
      "icd10": ["N10", "N12"],
      "severity": ["moderate", "severe"],
      "shortDescription": "Acute bacterial infection of the renal parenchyma and collecting system",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "clinical_presentation": "Fever, chills, flank pain, costovertebral angle tenderness, nausea/vomiting. May have dysuria and urinary frequency.",
            "diagnostic_criteria": "Clinical symptoms + pyuria + positive urine culture (≥10⁴ CFU/mL).",
            "red_flags": [
              "Septic shock",
              "Obstructive uropathy (requires urgent drainage)",
              "Pregnancy",
              "Immunosuppression",
              "Renal abscess or emphysematous pyelonephritis"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "All patients: Urine culture before antibiotics. Blood cultures if hospitalized or severe.",
            "essential_tests": [
              "Urinalysis",
              "Urine culture with susceptibilities",
              "Blood cultures (2 sets) if hospitalized",
              "CBC, CMP (assess renal function)"
            ],
            "conditional_tests": [
              "CT abdomen/pelvis with contrast (if concern for abscess, obstruction, or emphysematous pyelonephritis)",
              "Renal ultrasound (if CT contraindicated)"
            ],
            "turnaround_time": "Urine culture: 24-48 hours. Blood cultures: 24-48 hours. CT: Same day."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (80-90%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp."
            ],
            "resistance_patterns": "Similar to cystitis but higher rates of ESBL and fluoroquinolone resistance in hospitalized patients",
            "mdro_risk_factors": [
              "Recent hospitalization",
              "Recent antibiotic use",
              "Urologic abnormalities",
              "Recurrent UTIs"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "outpatient_mild": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily (if local resistance <10%)",
              "hospitalized_moderate": "Ceftriaxone 1-2g IV daily OR Cefepime 1-2g IV q8-12h",
              "severe_septic": "Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (if ESBL risk)"
            },
            "alternatives": "Fluoroquinolone allergy: Ceftriaxone or cefepime. ESBL risk: Meropenem or ertapenem.",
            "avoid_list": "Avoid nitrofurantoin (does not achieve adequate tissue levels for pyelonephritis)"
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ciprofloxacin, levofloxacin, or ceftriaxone (based on susceptibility)",
              "ESBL_E_coli": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily",
              "Enterococcus": "Ampicillin 2g IV q6h (if susceptible) OR Vancomycin (if VRE)"
            },
            "de_escalation": "Switch to oral fluoroquinolone or TMP-SMX once afebrile and clinically stable",
            "iv_to_po_switch": "Criteria: Afebrile >24h, tolerating PO, clinically stable, pathogen susceptible to oral agent"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "7-14 days total (IV + PO)",
            "short_course": "7 days if uncomplicated and good response",
            "prolonged": "14 days if bacteremia, delayed response, or complications"
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Adjust fluoroquinolones, beta-lactams for CrCl <30 mL/min",
            "pregnancy": "Preferred: Ceftriaxone, cefepime. Avoid: Fluoroquinolones. Hospitalize all pregnant women with pyelonephritis.",
            "obstruction": "Urgent urology consult for drainage (nephrostomy or stent) if obstructive uropathy"
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results at 48-72 hours",
              "De-escalate to narrow-spectrum oral agent",
              "Switch IV to PO when clinically stable",
              "Reassess duration (avoid >14 days unless complicated)"
            ],
            "iv_to_po_opportunities": "Most patients can switch to PO by day 2-3 if afebrile and stable"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Pyelonephritis Guidelines (2010, reaffirmed 2019)",
              "url": "https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-in-women/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "CDC Healthcare-Associated Infections - UTI",
              "url": "https://www.cdc.gov/hai/ca_uti/uti.html"
            }
          ]
        }
      }
    },
    {
      "id": "complicated-uti",
      "name": "Complicated UTI",
      "synonyms": ["cUTI", "complicated urinary tract infection"],
      "icd10": ["N39.0", "N30.80"],
      "severity": ["moderate", "severe"],
      "shortDescription": "UTI in patients with structural/functional urinary tract abnormalities, immunosuppression, or healthcare-associated factors",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "UTI occurring in patients with factors that increase risk of treatment failure: structural/functional urinary tract abnormalities, immunosuppression, male sex, pregnancy, indwelling catheter, recent instrumentation, or healthcare-associated acquisition.",
            "clinical_presentation": "Variable: May present like uncomplicated cystitis or pyelonephritis, but with higher risk of complications, bacteremia, and treatment failure. Symptoms: Dysuria, frequency, urgency, fever, flank pain.",
            "diagnostic_criteria": "Clinical symptoms + pyuria + positive urine culture (≥10⁴ CFU/mL). Consider imaging if concern for obstruction or abscess.",
            "red_flags": [
              "Septic shock or hemodynamic instability",
              "Obstructive uropathy (requires urgent drainage)",
              "Renal abscess or emphysematous pyelonephritis",
              "Immunosuppression (transplant, chemotherapy, HIV)",
              "Persistent fever >72 hours despite antibiotics"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "ALWAYS obtain urine culture before antibiotics in complicated UTI. Blood cultures if hospitalized or severe.",
            "essential_tests": [
              "Urinalysis",
              "Urine culture with susceptibilities (MANDATORY)",
              "Blood cultures (2 sets) if hospitalized or severe",
              "CBC, CMP (assess renal function, WBC)"
            ],
            "conditional_tests": [
              "CT abdomen/pelvis with contrast: If concern for obstruction, abscess, emphysematous pyelonephritis, or no improvement in 72h",
              "Renal ultrasound: If CT contraindicated or to assess for hydronephrosis",
              "Post-void residual: If concern for urinary retention"
            ],
            "specimen_collection": "Midstream clean-catch preferred. If catheterized, obtain fresh specimen (not from bag).",
            "turnaround_time": "Urine culture: 24-48 hours. Blood cultures: 24-48 hours. CT: Same day if urgent."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (50-70%, lower than uncomplicated)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp. (especially VRE in healthcare-associated)",
              "Pseudomonas aeruginosa (catheter, instrumentation)",
              "Candida spp. (immunosuppressed, prolonged catheter)"
            ],
            "resistance_patterns": "Higher rates of ESBL (15-30%), fluoroquinolone resistance (20-40%), and multidrug resistance compared to uncomplicated UTI. Pseudomonas often resistant to fluoroquinolones and cephalosporins.",
            "mdro_risk_factors": [
              "Recent hospitalization (90 days)",
              "Recent antibiotic use (90 days)",
              "Indwelling catheter or urologic instrumentation",
              "Recurrent UTIs",
              "International travel (especially South Asia)",
              "Known MDRO colonization"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "mild_outpatient": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily (if local resistance <10% and no recent fluoroquinolone use)",
              "moderate_hospitalized": "Ceftriaxone 1-2g IV daily OR Cefepime 2g IV q8-12h",
              "severe_or_ESBL_risk": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily OR Piperacillin-tazobactam 3.375g IV q6h (if Pseudomonas risk)"
            },
            "alternatives": "Beta-lactam allergy: Aztreonam 1-2g IV q8h + vancomycin 15-20mg/kg IV q8-12h (for Gram-positive coverage). Fluoroquinolone allergy: Ceftriaxone or cefepime.",
            "avoid_list": "Avoid nitrofurantoin (inadequate tissue levels for complicated UTI). Avoid fosfomycin (not FDA-approved for complicated UTI).",
            "pseudomonas_coverage": "If risk factors (catheter, recent instrumentation, prior Pseudomonas): Use cefepime, piperacillin-tazobactam, or meropenem."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily OR Ceftriaxone 1g IV daily",
              "ESBL_producing": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily (preferred for ESBL)",
              "Pseudomonas_aeruginosa": "Cefepime 2g IV q8h OR Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (based on susceptibility)",
              "Enterococcus": "Ampicillin 2g IV q6h (if susceptible) OR Vancomycin 15-20mg/kg IV q8-12h (if VRE or ampicillin-resistant)",
              "Candida": "Fluconazole 400mg PO/IV daily (if susceptible) OR Micafungin 100mg IV daily (if azole-resistant)"
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results. Avoid prolonged broad-spectrum therapy.",
            "iv_to_po_switch": "Criteria: Afebrile >24-48h, tolerating PO, clinically stable, pathogen susceptible to oral agent with good bioavailability."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "7-14 days total (IV + PO)",
            "short_course": "7 days if uncomplicated course and good response",
            "prolonged": "14 days if bacteremia, delayed response, obstruction, abscess, or immunosuppression. Consider 21 days for renal abscess or emphysematous pyelonephritis."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Adjust all antibiotics for CrCl <30 mL/min. Avoid nitrofurantoin if CrCl <30 mL/min.",
            "immunosuppression": "Longer duration (14 days). Consider fungal coverage if prolonged catheter or recent broad-spectrum antibiotics. Consult ID if transplant recipient.",
            "obstruction": "URGENT urology consult for drainage (nephrostomy, stent, or Foley). Antibiotics alone will fail without source control.",
            "catheter_management": "Remove or replace catheter if possible. Do NOT treat asymptomatic bacteriuria in catheterized patients unless pre-procedure.",
            "male_patients": "All UTIs in men are considered complicated. Rule out prostatitis (tender prostate on exam, elevated PSA)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results at 48-72 hours and de-escalate",
              "Switch IV to PO when clinically stable (usually day 2-4)",
              "Reassess duration: Avoid >14 days unless abscess or bacteremia",
              "Remove or replace catheter if possible",
              "Imaging if no improvement in 72 hours"
            ],
            "iv_to_po_opportunities": "Most patients can switch to PO by day 2-4 if afebrile and stable. Oral options: Ciprofloxacin, levofloxacin, TMP-SMX (if susceptible).",
            "avoid_unnecessary_treatment": "Do NOT treat asymptomatic bacteriuria (except pregnancy or pre-urologic procedure). Do NOT treat catheter colonization without symptoms."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Complicated UTI Guidelines (2010, updated 2019)",
              "url": "https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/"
            },
            {
              "label": "EAU Guidelines on Urological Infections (2024)",
              "url": "https://uroweb.org/guidelines/urological-infections"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "recurrent-uti",
      "name": "Recurrent UTI",
      "synonyms": ["rUTI", "recurrent cystitis", "frequent UTIs"],
      "icd10": ["N30.90", "N39.0"],
      "severity": ["mild", "moderate"],
      "shortDescription": "≥2 UTIs in 6 months or ≥3 UTIs in 12 months in women",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Recurrent UTI (rUTI) defined as ≥2 UTIs in 6 months OR ≥3 UTIs in 12 months. Most are reinfections (new infection with different organism) rather than relapse (same organism).",
            "clinical_presentation": "Typical cystitis symptoms: Dysuria, frequency, urgency, suprapubic pain. Recurrent episodes with similar symptoms. May have identifiable triggers (sexual activity, spermicide use, menopause).",
            "diagnostic_criteria": "History of documented recurrent UTIs + current symptoms + pyuria or positive urine culture.",
            "risk_factors": [
              "Sexual activity (especially with spermicide use)",
              "Postmenopausal status (estrogen deficiency)",
              "History of UTI before age 15",
              "Maternal history of UTI",
              "Diabetes mellitus",
              "Incomplete bladder emptying",
              "Urinary incontinence"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Urine culture recommended for each episode to document infection and guide therapy. Consider urologic evaluation if ≥3 UTIs/year or risk factors for complications.",
            "essential_tests": [
              "Urinalysis",
              "Urine culture with susceptibilities (for each episode)",
              "Post-void residual (PVR) if concern for incomplete emptying"
            ],
            "conditional_tests": [
              "Renal ultrasound: If concern for structural abnormality or stones",
              "Cystoscopy: If hematuria, age >50, or concern for bladder pathology",
              "Urodynamic studies: If urinary retention or neurogenic bladder suspected",
              "Vaginal exam: If postmenopausal (assess for atrophic vaginitis)"
            ],
            "when_not_to_test": "Do NOT culture asymptomatic bacteriuria between episodes. Do NOT perform routine imaging in young women with typical rUTI.",
            "turnaround_time": "Urine culture: 24-48 hours. Imaging: 1-7 days (non-urgent)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (80-85%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Staphylococcus saprophyticus",
              "Enterococcus spp."
            ],
            "resistance_patterns": "May have higher resistance rates due to repeated antibiotic exposure. TMP-SMX resistance: 20-30%. Fluoroquinolone resistance: 15-25%. Consider local antibiogram.",
            "mdro_risk_factors": [
              "Frequent antibiotic use",
              "Recent hospitalization",
              "International travel",
              "Known MDRO colonization"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "acute_episode": "Nitrofurantoin 100mg PO BID x 5 days OR TMP-SMX DS PO BID x 3 days (if local resistance <20% and no recent use)",
              "alternative": "Fosfomycin 3g PO single dose OR Cephalexin 500mg PO QID x 5-7 days"
            },
            "alternatives": "If recent antibiotic use or known resistance: Base on prior culture results. Consider rotating antibiotic classes.",
            "avoid_list": "Avoid fluoroquinolones for uncomplicated rUTI (reserve for complicated UTI/pyelonephritis). Avoid same antibiotic used in previous episode if <3 months."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Continue empiric therapy if susceptible. Consider rotating antibiotic classes for future episodes.",
              "multidrug_resistant": "Base on susceptibility testing. May require fluoroquinolone or beta-lactam if resistant to first-line agents.",
              "ESBL_producing": "Nitrofurantoin (if susceptible) OR Fosfomycin OR Ertapenem 1g IV daily x 3-5 days (if severe)"
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results.",
            "iv_to_po_switch": "Not applicable (oral therapy for uncomplicated rUTI)"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "3-7 days for acute episodes (same as uncomplicated cystitis)",
            "short_course": "TMP-SMX: 3 days. Fosfomycin: Single dose.",
            "prolonged": "Nitrofurantoin: 5-7 days. Consider 7 days if slow response."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "prophylaxis_indications": "Consider prophylaxis if ≥2 UTIs in 6 months or ≥3 UTIs in 12 months AND significantly impacting quality of life.",
            "prophylaxis_options": {
              "continuous": "Nitrofurantoin 50-100mg PO daily OR TMP-SMX SS (half-strength) PO daily OR Cephalexin 250mg PO daily. Duration: 6-12 months, then reassess.",
              "post_coital": "Nitrofurantoin 50-100mg PO OR TMP-SMX SS PO OR Cephalexin 250mg PO within 2 hours after intercourse (if UTIs related to sexual activity)",
              "self_start_therapy": "Patient-initiated therapy at first symptom (for reliable patients with typical symptoms)"
            },
            "non_antibiotic_prevention": [
              "Increase fluid intake (1.5-2L/day)",
              "Void after intercourse",
              "Avoid spermicides",
              "Cranberry products (modest benefit, 36-72mg PAC daily)",
              "Vaginal estrogen (postmenopausal women): Estriol 0.5mg intravaginal 2x/week",
              "D-mannose 2g daily (emerging evidence)",
              "Methenamine hippurate 1g PO BID (if urine pH <6)"
            ],
            "postmenopausal_women": "Vaginal estrogen therapy (estriol cream or ring) reduces rUTI by 50-75%. Preferred over antibiotic prophylaxis in postmenopausal women."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Reassess need for prophylaxis after 6-12 months",
              "Encourage non-antibiotic prevention strategies",
              "Avoid prolonged antibiotic prophylaxis (>12 months) without reassessment",
              "Consider vaginal estrogen in postmenopausal women before antibiotic prophylaxis"
            ],
            "avoid_unnecessary_treatment": "Do NOT treat asymptomatic bacteriuria between episodes. Do NOT use prophylaxis for <2 UTIs in 6 months.",
            "patient_education": "Educate on behavioral modifications: Hydration, post-coital voiding, avoid spermicides, cranberry products, vaginal estrogen (if postmenopausal)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "AUA Recurrent UTI Guidelines (2019)",
              "url": "https://www.auanet.org/guidelines/recurrent-uti"
            },
            {
              "label": "IDSA Uncomplicated Cystitis Guidelines (2010, reaffirmed 2019)",
              "url": "https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-in-women/"
            },
            {
              "label": "Cochrane Review: Cranberry for Preventing UTIs (2023)",
              "url": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001321.pub6/full"
            }
          ]
        }
      }
    },
    {
      "id": "cauti",
      "name": "Catheter-Associated UTI (CAUTI)",
      "synonyms": ["CAUTI", "catheter UTI", "catheter-related infection"],
      "icd10": ["N39.0", "T83.51XA"],
      "severity": ["moderate", "severe"],
      "shortDescription": "Symptomatic UTI in patient with indwelling urinary catheter or catheter removed within 48 hours",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "CAUTI is a UTI occurring in a patient with an indwelling urinary catheter (Foley, suprapubic, or intermittent catheterization) OR within 48 hours of catheter removal, with symptoms attributable to the UTI.",
            "clinical_presentation": "Fever (>38°C), suprapubic tenderness, costovertebral angle tenderness, altered mental status (especially elderly), rigors, or new-onset delirium. NOTE: Cloudy or foul-smelling urine alone is NOT sufficient for diagnosis.",
            "diagnostic_criteria": "Indwelling catheter (or removed <48h) + symptoms (fever, suprapubic pain, CVA tenderness, delirium) + pyuria (≥10 WBC/hpf) + positive urine culture (≥10³ CFU/mL of ≥1 bacterial species).",
            "red_flags": [
              "Septic shock or hemodynamic instability",
              "Obstructive uropathy",
              "Immunosuppression",
              "Persistent fever >72 hours despite antibiotics",
              "Bacteremia (positive blood cultures)"
            ],
            "do_not_treat": "Asymptomatic bacteriuria (catheter colonization) - Do NOT treat unless patient is undergoing urologic procedure or is pregnant."
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "ONLY test if patient has symptoms. Do NOT screen for asymptomatic bacteriuria in catheterized patients.",
            "essential_tests": [
              "Urinalysis (from fresh catheter specimen, NOT from bag)",
              "Urine culture with susceptibilities (MANDATORY before antibiotics)",
              "Blood cultures (2 sets) if fever or severe",
              "CBC, CMP (assess renal function, WBC)"
            ],
            "conditional_tests": [
              "CT abdomen/pelvis: If no improvement in 72h or concern for abscess/obstruction",
              "Renal ultrasound: If CT contraindicated"
            ],
            "specimen_collection": "Obtain urine from catheter port (NOT from drainage bag). If long-term catheter, consider replacing catheter before obtaining specimen.",
            "turnaround_time": "Urine culture: 24-48 hours. Blood cultures: 24-48 hours.",
            "interpretation": "Pyuria is ALWAYS present with catheter. Positive culture alone (without symptoms) = colonization, NOT infection."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (30-50%, lower than community UTI)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp. (especially VRE)",
              "Pseudomonas aeruginosa (15-20%)",
              "Candida spp. (5-10%, especially if prolonged catheter or antibiotics)"
            ],
            "polymicrobial": "30-40% of CAUTI are polymicrobial. Treat all significant pathogens.",
            "resistance_patterns": "High rates of multidrug resistance: ESBL (20-30%), fluoroquinolone resistance (30-50%), VRE (10-20%). Pseudomonas often resistant to fluoroquinolones and cephalosporins.",
            "mdro_risk_factors": [
              "Prolonged catheterization (>7 days)",
              "Recent hospitalization or nursing home residence",
              "Recent antibiotic use (90 days)",
              "Known MDRO colonization",
              "ICU admission"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "mild_moderate": "Ceftriaxone 1-2g IV daily OR Cefepime 2g IV q8-12h (covers Pseudomonas)",
              "severe_or_MDRO_risk": "Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (if ESBL risk or recent carbapenem-resistant organism)"
            },
            "enterococcal_coverage": "Add vancomycin 15-20mg/kg IV q8-12h if risk factors for VRE (prolonged hospitalization, prior VRE, ICU) OR if Gram-positive cocci in urine Gram stain.",
            "alternatives": "Beta-lactam allergy: Aztreonam 1-2g IV q8h (Gram-negative) + vancomycin 15-20mg/kg IV q8-12h (Gram-positive).",
            "avoid_list": "Avoid nitrofurantoin (inadequate tissue levels). Avoid fosfomycin (not FDA-approved for CAUTI). Avoid fluoroquinolones as empiric therapy (high resistance rates).",
            "candida_coverage": "If Candida in urine culture + symptoms + no other pathogen: Fluconazole 400mg PO/IV daily (if susceptible) OR Micafungin 100mg IV daily (if azole-resistant or critically ill)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ceftriaxone 1g IV daily OR Ciprofloxacin 400mg IV q12h (if susceptible)",
              "ESBL_producing": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily",
              "Pseudomonas_aeruginosa": "Cefepime 2g IV q8h OR Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (based on susceptibility)",
              "Enterococcus_faecalis": "Ampicillin 2g IV q6h (if susceptible)",
              "VRE": "Linezolid 600mg PO/IV q12h OR Daptomycin 6mg/kg IV daily",
              "Candida": "Fluconazole 400mg PO/IV daily (if susceptible) OR Micafungin 100mg IV daily"
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results. Discontinue vancomycin if no VRE.",
            "iv_to_po_switch": "Criteria: Afebrile >24-48h, tolerating PO, clinically stable, pathogen susceptible to oral agent. Options: Ciprofloxacin, levofloxacin, TMP-SMX, fluconazole (for Candida)."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "7 days if prompt resolution and catheter removed",
            "short_course": "5-7 days if catheter removed and good response",
            "prolonged": "10-14 days if catheter remains in place, delayed response, or bacteremia. Consider 14 days for Pseudomonas or Candida."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "catheter_management": "REMOVE or REPLACE catheter as soon as possible. Antibiotics alone (without catheter removal) have higher failure rates. If catheter must remain, replace it before starting antibiotics.",
            "source_control": "Catheter removal is the most important intervention. Consider alternatives: Intermittent catheterization, condom catheter (men), or bladder training.",
            "renal_dose": "Adjust all antibiotics for CrCl <30 mL/min.",
            "immunosuppression": "Longer duration (10-14 days). Consider fungal coverage if prolonged catheter or recent broad-spectrum antibiotics.",
            "spinal_cord_injury": "Higher risk of CAUTI. Consider intermittent catheterization instead of indwelling catheter. Do NOT treat asymptomatic bacteriuria."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results at 48-72 hours and de-escalate",
              "REMOVE catheter if no longer needed (most important intervention)",
              "Switch IV to PO when clinically stable (usually day 2-4)",
              "Reassess duration: 7 days if catheter removed, 10-14 days if remains",
              "Discontinue vancomycin if no VRE"
            ],
            "iv_to_po_opportunities": "Most patients can switch to PO by day 2-4 if afebrile and stable. Oral options: Ciprofloxacin, levofloxacin, TMP-SMX (if susceptible).",
            "avoid_unnecessary_treatment": "Do NOT treat asymptomatic bacteriuria (catheter colonization). Do NOT culture urine without symptoms. Do NOT use prophylactic antibiotics in catheterized patients.",
            "prevention": [
              "Use catheters only when necessary (avoid for incontinence or convenience)",
              "Remove catheters as soon as possible",
              "Maintain closed drainage system",
              "Hand hygiene before catheter manipulation",
              "Consider alternatives: Intermittent catheterization, condom catheter"
            ]
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA CAUTI Guidelines (2009, updated 2019)",
              "url": "https://www.idsociety.org/practice-guideline/catheter-associated-urinary-tract-infections/"
            },
            {
              "label": "CDC CAUTI Prevention Guidelines (2024)",
              "url": "https://www.cdc.gov/hai/ca_uti/uti.html"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "acute-prostatitis",
      "name": "Acute Bacterial Prostatitis",
      "synonyms": ["ABP", "acute prostatitis", "prostate infection"],
      "icd10": ["N41.0"],
      "severity": ["moderate", "severe"],
      "shortDescription": "Acute bacterial infection of the prostate gland in men",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Acute bacterial prostatitis (ABP) is an acute infection of the prostate gland, typically presenting with fever, pelvic pain, and urinary symptoms. Can progress to sepsis if untreated.",
            "clinical_presentation": "Fever, chills, dysuria, urinary frequency/urgency, perineal or suprapubic pain, low back pain, myalgias. May have urinary retention. Digital rectal exam (DRE): Tender, boggy, swollen prostate (AVOID vigorous exam - risk of bacteremia).",
            "diagnostic_criteria": "Clinical symptoms + tender prostate on DRE + pyuria + positive urine culture. Elevated PSA (not diagnostic, returns to baseline after treatment).",
            "red_flags": [
              "Septic shock or hemodynamic instability",
              "Acute urinary retention (requires catheterization)",
              "Prostatic abscess (suspect if persistent fever >72h despite antibiotics)",
              "Immunosuppression",
              "Recent urologic instrumentation"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "All patients: Urine culture before antibiotics. Blood cultures if hospitalized or severe. AVOID vigorous prostate massage (risk of bacteremia).",
            "essential_tests": [
              "Urinalysis",
              "Urine culture with susceptibilities (MANDATORY)",
              "Blood cultures (2 sets) if fever or severe",
              "CBC, CMP (assess renal function, WBC)",
              "PSA (elevated in acute phase, recheck after treatment)"
            ],
            "conditional_tests": [
              "Transrectal ultrasound (TRUS) or CT pelvis: If concern for prostatic abscess (persistent fever >72h)",
              "Post-void residual: If concern for urinary retention",
              "STI testing (gonorrhea, chlamydia): If age <35 or sexually active"
            ],
            "specimen_collection": "Midstream urine (pre-massage). AVOID vigorous prostate massage in acute phase.",
            "turnaround_time": "Urine culture: 24-48 hours. Blood cultures: 24-48 hours. Imaging: Same day if abscess suspected."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (75-80%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp.",
              "Pseudomonas aeruginosa (especially if recent instrumentation)",
              "Neisseria gonorrhoeae, Chlamydia trachomatis (if age <35 or STI risk)"
            ],
            "resistance_patterns": "Similar to complicated UTI. Fluoroquinolone resistance: 15-25%. ESBL: 10-20% (higher if healthcare-associated).",
            "mdro_risk_factors": [
              "Recent hospitalization or urologic instrumentation",
              "Recent antibiotic use (90 days)",
              "Recurrent prostatitis",
              "Known MDRO colonization"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "outpatient_mild": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily (fluoroquinolones have excellent prostate penetration)",
              "hospitalized_moderate": "Ceftriaxone 1-2g IV daily + Doxycycline 100mg PO/IV BID (if STI risk) OR Ciprofloxacin 400mg IV q12h",
              "severe_septic": "Piperacillin-tazobactam 3.375g IV q6h OR Ceftriaxone 2g IV daily + Gentamicin 5-7mg/kg IV daily"
            },
            "sti_coverage": "If age <35 or sexually active: Add doxycycline 100mg PO BID OR ceftriaxone 500mg IM single dose (for gonorrhea).",
            "alternatives": "Fluoroquinolone allergy: TMP-SMX DS PO BID (good prostate penetration) OR Doxycycline 100mg PO BID.",
            "avoid_list": "Avoid nitrofurantoin (poor prostate penetration). Avoid fosfomycin (inadequate prostate levels)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily OR TMP-SMX DS PO BID (if susceptible)",
              "ESBL_producing": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily (then switch to PO if susceptible to ciprofloxacin or TMP-SMX)",
              "Pseudomonas_aeruginosa": "Ciprofloxacin 400mg IV q12h OR Cefepime 2g IV q8h (based on susceptibility)",
              "Enterococcus": "Ampicillin 2g IV q6h (if susceptible) OR Vancomycin 15-20mg/kg IV q8-12h (if VRE)",
              "Gonorrhea": "Ceftriaxone 500mg IM single dose + Doxycycline 100mg PO BID x 10 days",
              "Chlamydia": "Doxycycline 100mg PO BID x 10-14 days"
            },
            "de_escalation": "Switch to oral fluoroquinolone or TMP-SMX once afebrile and clinically stable.",
            "iv_to_po_switch": "Criteria: Afebrile >24-48h, tolerating PO, clinically stable, pathogen susceptible to oral agent with good prostate penetration."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "4-6 weeks total (IV + PO) - Prolonged duration needed for prostate penetration and eradication",
            "short_course": "4 weeks if uncomplicated and good response",
            "prolonged": "6 weeks if bacteremia, delayed response, or prostatic abscess. Consider 8-12 weeks if abscess drained."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "urinary_retention": "If acute urinary retention: Place suprapubic catheter (preferred) OR Foley catheter. Avoid urethral catheterization if possible (risk of bacteremia).",
            "prostatic_abscess": "Suspect if persistent fever >72h despite antibiotics. Diagnosis: TRUS or CT pelvis. Treatment: Drainage (TRUS-guided aspiration or TURP) + prolonged antibiotics (6-8 weeks).",
            "renal_dose": "Adjust fluoroquinolones, TMP-SMX for CrCl <30 mL/min.",
            "sti_risk": "If age <35 or sexually active: Test for gonorrhea and chlamydia. Treat empirically if high suspicion.",
            "recurrence": "If recurrent ABP: Consider chronic bacterial prostatitis. Longer duration (6-12 weeks) and urologic evaluation."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results at 48-72 hours and de-escalate",
              "Switch IV to PO when clinically stable (usually day 2-4)",
              "Ensure total duration is 4-6 weeks (prostate penetration requires prolonged therapy)",
              "Imaging if no improvement in 72 hours (rule out abscess)",
              "Recheck PSA after treatment (should normalize)"
            ],
            "iv_to_po_opportunities": "Most patients can switch to PO by day 2-4 if afebrile and stable. Oral options: Ciprofloxacin, levofloxacin, TMP-SMX (if susceptible).",
            "avoid_unnecessary_treatment": "Do NOT treat asymptomatic bacteriuria. Do NOT use short-course therapy (<4 weeks) - high relapse rate."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Prostatitis Guidelines (2015)",
              "url": "https://www.idsociety.org/practice-guideline/prostatitis/"
            },
            {
              "label": "EAU Guidelines on Urological Infections (2024)",
              "url": "https://uroweb.org/guidelines/urological-infections"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "chronic-prostatitis",
      "name": "Chronic Bacterial Prostatitis",
      "synonyms": ["CBP", "chronic prostatitis", "recurrent prostatitis"],
      "icd10": ["N41.1"],
      "severity": ["mild", "moderate"],
      "shortDescription": "Chronic or recurrent bacterial infection of the prostate gland",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Chronic bacterial prostatitis (CBP) is a recurrent or persistent bacterial infection of the prostate, characterized by recurrent UTIs with the same organism. Accounts for 5-10% of chronic prostatitis cases.",
            "clinical_presentation": "Recurrent UTIs (same organism), pelvic/perineal pain, dysuria, urinary frequency/urgency, low back pain, post-ejaculatory pain. Symptoms are typically less severe than acute prostatitis. DRE: May be normal or show mild tenderness.",
            "diagnostic_criteria": "Recurrent UTIs with same organism + positive post-prostate massage urine culture (≥10-fold higher CFU than pre-massage urine). Symptoms >3 months.",
            "differential_diagnosis": [
              "Chronic pelvic pain syndrome (CPPS) - Most common (90-95% of chronic prostatitis)",
              "Benign prostatic hyperplasia (BPH)",
              "Bladder cancer",
              "Urethral stricture",
              "Interstitial cystitis"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Obtain urine culture before and after prostate massage (Meares-Stamey 4-glass test or simplified 2-glass test). Culture during symptomatic episodes.",
            "essential_tests": [
              "Pre-massage urine culture (VB1 or VB2)",
              "Post-prostate massage urine culture (VB3 or expressed prostatic secretions)",
              "Urinalysis",
              "PSA (may be elevated, recheck after treatment)"
            ],
            "conditional_tests": [
              "Transrectal ultrasound (TRUS): If concern for prostatic calculi or abscess",
              "Cystoscopy: If hematuria or concern for bladder pathology",
              "Urodynamic studies: If voiding dysfunction",
              "STI testing: If age <35 or sexually active"
            ],
            "meares_stamey_test": "4-glass test: VB1 (first 10mL urine), VB2 (midstream urine), EPS (expressed prostatic secretions after massage), VB3 (first 10mL urine after massage). CBP: VB3 or EPS has ≥10-fold higher CFU than VB1/VB2.",
            "turnaround_time": "Urine culture: 24-48 hours. Imaging: 1-7 days (non-urgent)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (65-80%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp.",
              "Pseudomonas aeruginosa (less common)",
              "Enterobacter spp."
            ],
            "resistance_patterns": "Higher resistance rates due to repeated antibiotic exposure. Fluoroquinolone resistance: 20-30%. TMP-SMX resistance: 15-25%.",
            "mdro_risk_factors": [
              "Frequent antibiotic use",
              "Recurrent UTIs",
              "Recent hospitalization or instrumentation",
              "Known MDRO colonization"
            ],
            "biofilm_formation": "Bacteria in prostate may form biofilms, making eradication difficult. Prostatic calculi can harbor bacteria."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "preferred": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily (fluoroquinolones have excellent prostate penetration)",
              "alternative": "TMP-SMX DS PO BID (if local resistance <20% and no recent use)"
            },
            "alternatives": "Doxycycline 100mg PO BID (if fluoroquinolone allergy or resistance). Azithromycin 500mg PO daily (if intolerant to other agents).",
            "avoid_list": "Avoid nitrofurantoin (poor prostate penetration). Avoid fosfomycin (inadequate prostate levels). Avoid beta-lactams (poor prostate penetration except in acute inflammation)."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ciprofloxacin 500mg PO BID OR Levofloxacin 750mg PO daily OR TMP-SMX DS PO BID (if susceptible)",
              "fluoroquinolone_resistant": "TMP-SMX DS PO BID (if susceptible) OR Doxycycline 100mg PO BID",
              "ESBL_producing": "Difficult to treat. Consider prolonged course of ciprofloxacin or TMP-SMX if susceptible. May require IV ertapenem 1g daily x 2-4 weeks then PO suppression.",
              "Enterococcus": "Amoxicillin 500mg PO TID OR Doxycycline 100mg PO BID",
              "Pseudomonas": "Ciprofloxacin 500-750mg PO BID (if susceptible). May require IV therapy initially."
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results.",
            "iv_to_po_switch": "Rarely need IV therapy for CBP (unlike acute prostatitis). Use PO agents with good prostate penetration."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "6-12 weeks (prolonged duration needed for prostate penetration and biofilm eradication)",
            "short_course": "6 weeks minimum (shorter courses have high relapse rates)",
            "prolonged": "12 weeks if recurrent or persistent symptoms. Some patients may require suppressive therapy (low-dose daily antibiotics) if recurrent despite adequate treatment.",
            "suppressive_therapy": "If ≥3 relapses despite adequate treatment: Consider long-term suppressive therapy with ciprofloxacin 250mg PO daily OR TMP-SMX SS PO daily. Reassess every 6-12 months."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Adjust fluoroquinolones, TMP-SMX for CrCl <30 mL/min.",
            "prostatic_calculi": "Prostatic stones can harbor bacteria and prevent eradication. Consider TURP if recurrent despite adequate antibiotics.",
            "alpha_blockers": "Consider adding alpha-blocker (tamsulosin 0.4mg PO daily) to improve urinary symptoms and prostate drainage. May improve antibiotic penetration.",
            "nsaids": "NSAIDs (ibuprofen, naproxen) may help with pelvic pain and inflammation.",
            "pelvic_floor_therapy": "Consider pelvic floor physical therapy if chronic pelvic pain persists despite antibiotics (may have CPPS component).",
            "surgical_options": "TURP (transurethral resection of prostate) may be considered if recurrent despite medical therapy, especially if prostatic calculi present."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results and de-escalate to narrow-spectrum agent",
              "Ensure adequate duration (6-12 weeks minimum)",
              "Reassess at 6 weeks: If symptoms persist, consider longer course or urologic evaluation",
              "Avoid repeated short courses (<6 weeks) - high relapse rate",
              "Consider suppressive therapy only if ≥3 relapses despite adequate treatment"
            ],
            "avoid_unnecessary_treatment": "Do NOT treat asymptomatic bacteriuria. Do NOT use short-course therapy (<6 weeks). Distinguish CBP from chronic pelvic pain syndrome (CPPS) - CPPS does NOT require antibiotics.",
            "patient_education": "Educate on prolonged treatment duration (6-12 weeks). Advise on symptom management (alpha-blockers, NSAIDs, pelvic floor therapy). Discuss risk of relapse and need for follow-up."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Prostatitis Guidelines (2015)",
              "url": "https://www.idsociety.org/practice-guideline/prostatitis/"
            },
            {
              "label": "EAU Guidelines on Urological Infections (2024)",
              "url": "https://uroweb.org/guidelines/urological-infections"
            },
            {
              "label": "AUA Chronic Prostatitis Guidelines (2018)",
              "url": "https://www.auanet.org/guidelines/chronic-prostatitis"
            }
          ]
        }
      }
    },
    {
      "id": "uti-pregnancy",
      "name": "UTI in Pregnancy",
      "synonyms": ["pregnancy UTI", "gestational UTI", "asymptomatic bacteriuria in pregnancy"],
      "icd10": ["O23.4", "O23.0", "O23.1"],
      "severity": ["mild", "moderate", "severe"],
      "shortDescription": "Urinary tract infections during pregnancy, including asymptomatic bacteriuria, cystitis, and pyelonephritis",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "UTI in pregnancy includes: (1) Asymptomatic bacteriuria (ASB): ≥10⁵ CFU/mL without symptoms, (2) Acute cystitis: Symptomatic bladder infection, (3) Acute pyelonephritis: Upper tract infection with fever. Pregnancy increases risk of progression from ASB to pyelonephritis (20-40% if untreated).",
            "clinical_presentation": {
              "asymptomatic_bacteriuria": "NO symptoms. Detected on routine prenatal screening urine culture.",
              "acute_cystitis": "Dysuria, frequency, urgency, suprapubic pain. NO fever or flank pain.",
              "acute_pyelonephritis": "Fever, chills, flank pain, nausea/vomiting, costovertebral angle tenderness. May have contractions or preterm labor."
            },
            "diagnostic_criteria": "ASB: ≥10⁵ CFU/mL on 2 consecutive cultures without symptoms. Cystitis: Symptoms + pyuria + positive culture. Pyelonephritis: Fever + flank pain + pyuria + positive culture.",
            "red_flags": [
              "Preterm labor or contractions",
              "Septic shock",
              "Acute respiratory distress (rare complication of pyelonephritis in pregnancy)",
              "Persistent fever >72 hours despite antibiotics",
              "Fetal distress"
            ],
            "complications": "Untreated ASB → pyelonephritis (20-40%), preterm birth, low birth weight, perinatal mortality. Pyelonephritis → preterm labor, sepsis, ARDS (rare)."
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "SCREEN all pregnant women for ASB at first prenatal visit (12-16 weeks) with urine culture. Repeat if high risk. Test for symptomatic UTI anytime during pregnancy.",
            "essential_tests": [
              "Urine culture with susceptibilities (MANDATORY for all pregnant women at first visit)",
              "Urinalysis (if symptomatic)",
              "CBC, CMP (if pyelonephritis)",
              "Blood cultures (2 sets) if pyelonephritis"
            ],
            "conditional_tests": [
              "Renal ultrasound: If pyelonephritis not improving in 72h or concern for obstruction",
              "Fetal monitoring: If preterm labor or fetal distress",
              "Repeat urine culture: 1-2 weeks after treatment (test of cure)"
            ],
            "specimen_collection": "Clean-catch midstream urine. Avoid catheterization unless necessary.",
            "turnaround_time": "Urine culture: 24-48 hours. Blood cultures: 24-48 hours.",
            "screening_recommendation": "USPSTF Grade A recommendation: Screen all pregnant women for ASB at 12-16 weeks gestation."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (80-90%)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp.",
              "Group B Streptococcus (GBS) - Important in pregnancy"
            ],
            "resistance_patterns": "Similar to non-pregnant women. Ampicillin resistance: 30-50%. TMP-SMX resistance: 15-25%.",
            "gbs_colonization": "Group B Streptococcus (GBS) bacteriuria at any time during pregnancy = heavy colonization. Requires intrapartum antibiotic prophylaxis (IAP) during labor."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "asymptomatic_bacteriuria": {
              "first_line": "Nitrofurantoin 100mg PO BID x 5-7 days (AVOID in 3rd trimester, especially >36 weeks) OR Amoxicillin-clavulanate 500mg PO TID x 5-7 days OR Cephalexin 500mg PO QID x 5-7 days",
              "alternative": "Fosfomycin 3g PO single dose (if susceptible)"
            },
            "acute_cystitis": {
              "first_line": "Nitrofurantoin 100mg PO BID x 5-7 days (AVOID in 3rd trimester) OR Amoxicillin-clavulanate 500mg PO TID x 5-7 days OR Cephalexin 500mg PO QID x 5-7 days",
              "alternative": "Fosfomycin 3g PO single dose"
            },
            "acute_pyelonephritis": {
              "hospitalized": "Ceftriaxone 1-2g IV daily OR Cefepime 1-2g IV q8-12h OR Ampicillin 2g IV q6h + Gentamicin 5mg/kg IV daily (if severe)",
              "outpatient_mild": "Ceftriaxone 1g IV daily x 1-2 days, then cephalexin 500mg PO QID (if improving and afebrile)"
            },
            "avoid_list": "AVOID: Fluoroquinolones (teratogenic), TMP-SMX in 1st trimester (neural tube defects) and 3rd trimester (kernicterus), nitrofurantoin in 3rd trimester >36 weeks (hemolytic anemia in newborn), tetracyclines (bone/teeth effects).",
            "safe_in_pregnancy": "Safe: Penicillins, cephalosporins, fosfomycin, nitrofurantoin (except 3rd trimester), aztreonam."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Amoxicillin 500mg PO TID OR Cephalexin 500mg PO QID OR Nitrofurantoin 100mg PO BID (if <36 weeks)",
              "ampicillin_resistant": "Amoxicillin-clavulanate 500mg PO TID OR Cephalexin 500mg PO QID",
              "ESBL_producing": "Difficult in pregnancy. Consider IV ertapenem 1g daily (limited data but likely safe) OR prolonged ceftriaxone if susceptible.",
              "Enterococcus": "Ampicillin 500mg PO QID OR Amoxicillin 500mg PO TID",
              "GBS": "Ampicillin 500mg PO QID x 5-7 days. NOTE: GBS bacteriuria = heavy colonization, requires intrapartum antibiotic prophylaxis (IAP) during labor."
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results.",
            "iv_to_po_switch": "Criteria (pyelonephritis): Afebrile >24-48h, tolerating PO, no contractions, fetal well-being confirmed."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "asymptomatic_bacteriuria": "5-7 days (longer than non-pregnant women)",
            "acute_cystitis": "5-7 days (longer than non-pregnant women)",
            "acute_pyelonephritis": "10-14 days total (IV + PO). Hospitalize all pregnant women with pyelonephritis.",
            "test_of_cure": "MANDATORY: Repeat urine culture 1-2 weeks after treatment completion. If positive, retreat and consider suppressive therapy."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "hospitalization": "HOSPITALIZE all pregnant women with pyelonephritis. Consider hospitalization for cystitis if unable to tolerate PO, dehydration, or preterm labor.",
            "fetal_monitoring": "Monitor fetal well-being if pyelonephritis or preterm labor. Consider tocolytics if contractions.",
            "suppressive_therapy": "If recurrent UTI (≥2 episodes) or persistent ASB after 2 treatment courses: Consider suppressive therapy with nitrofurantoin 50-100mg PO daily OR cephalexin 250mg PO daily until delivery (AVOID nitrofurantoin after 36 weeks).",
            "gbs_management": "If GBS bacteriuria detected: Treat with appropriate antibiotic + intrapartum antibiotic prophylaxis (IAP) during labor (penicillin G 5 million units IV load, then 2.5-3 million units IV q4h until delivery).",
            "postpartum": "Reassess need for suppressive therapy postpartum. Most women do not need continued prophylaxis after delivery.",
            "renal_dose": "Adjust antibiotics for renal impairment (rare in pregnancy)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results and de-escalate to narrow-spectrum agent",
              "Ensure test of cure (repeat urine culture 1-2 weeks after treatment)",
              "Switch IV to PO when afebrile and stable (pyelonephritis)",
              "Reassess need for suppressive therapy if recurrent",
              "Document GBS bacteriuria for intrapartum antibiotic prophylaxis"
            ],
            "screening_compliance": "Ensure all pregnant women screened for ASB at 12-16 weeks. Treat all ASB in pregnancy (unlike non-pregnant women).",
            "avoid_teratogens": "AVOID fluoroquinolones, tetracyclines, TMP-SMX in 1st/3rd trimester, nitrofurantoin >36 weeks.",
            "patient_education": "Educate on importance of completing full course, test of cure, and reporting symptoms promptly. Discuss safe antibiotics in pregnancy."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "ACOG Practice Bulletin: UTI in Pregnancy (2020)",
              "url": "https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/06/urinary-tract-infections-in-pregnancy"
            },
            {
              "label": "IDSA Asymptomatic Bacteriuria Guidelines (2019)",
              "url": "https://www.idsociety.org/practice-guideline/asymptomatic-bacteriuria/"
            },
            {
              "label": "USPSTF Screening for ASB in Pregnancy (2019)",
              "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/asymptomatic-bacteriuria-in-adults-screening"
            }
          ]
        }
      }
    },
    {
      "id": "asymptomatic-bacteriuria",
      "name": "Asymptomatic Bacteriuria",
      "synonyms": ["ASB", "asymptomatic UTI", "bacteriuria without symptoms"],
      "icd10": ["N39.0", "R82.71"],
      "severity": ["mild"],
      "shortDescription": "Presence of bacteria in urine (≥10⁵ CFU/mL) without urinary symptoms - when to treat vs. not treat",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Asymptomatic bacteriuria (ASB) is the presence of ≥10⁵ CFU/mL of bacteria in urine WITHOUT symptoms of UTI (no dysuria, frequency, urgency, fever, or flank pain). Common in elderly, catheterized patients, and pregnant women.",
            "clinical_presentation": "NO symptoms. Detected incidentally on urine culture or urinalysis. Patient may have cloudy or foul-smelling urine, but this alone is NOT an indication for treatment.",
            "prevalence": "Elderly women: 10-20%. Elderly men: 5-10%. Nursing home residents: 25-50%. Catheterized patients: Nearly 100% if catheter >1 month. Pregnant women: 2-10%.",
            "diagnostic_criteria": "≥10⁵ CFU/mL on 2 consecutive urine cultures (women) or 1 culture (men) WITHOUT urinary symptoms.",
            "when_to_treat": [
              "Pregnancy (ALWAYS treat - prevents pyelonephritis and preterm birth)",
              "Before urologic procedures with mucosal trauma (TURP, cystoscopy with biopsy, stone removal)",
              "Kidney transplant recipients (first 3-6 months post-transplant)"
            ],
            "when_not_to_treat": [
              "Non-pregnant women",
              "Men (except before urologic procedures)",
              "Elderly (including nursing home residents)",
              "Diabetics",
              "Catheterized patients (except before catheter removal for urologic procedure)",
              "Spinal cord injury patients",
              "Patients with chronic kidney disease"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Do NOT screen for ASB in most populations. ONLY screen in pregnancy (12-16 weeks) and before urologic procedures with mucosal trauma.",
            "when_not_to_test": "Do NOT obtain urine cultures in asymptomatic patients (elderly, catheterized, diabetics, nursing home residents). Do NOT test urine from catheter bags.",
            "essential_tests": [
              "Urine culture with susceptibilities (if screening indicated: pregnancy or pre-procedure)"
            ],
            "conditional_tests": [
              "Urinalysis: NOT recommended for ASB screening (pyuria is common and does NOT indicate need for treatment)"
            ],
            "specimen_collection": "Clean-catch midstream urine (women). Midstream urine (men). Fresh catheter specimen if catheterized (NOT from bag).",
            "interpretation": "Pyuria (WBCs in urine) is COMMON with ASB and does NOT indicate need for treatment. Positive urine culture without symptoms = ASB, NOT infection."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Escherichia coli (most common)",
              "Klebsiella pneumoniae",
              "Proteus mirabilis",
              "Enterococcus spp.",
              "Coagulase-negative staphylococci",
              "Candida spp. (catheterized patients)"
            ],
            "polymicrobial": "Common in catheterized patients and elderly. Polymicrobial bacteriuria does NOT require treatment unless symptomatic.",
            "resistance_patterns": "Similar to symptomatic UTI. May have higher resistance rates in nursing home residents and catheterized patients."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "pregnancy": {
              "first_line": "Nitrofurantoin 100mg PO BID x 5-7 days (AVOID in 3rd trimester >36 weeks) OR Amoxicillin-clavulanate 500mg PO TID x 5-7 days OR Cephalexin 500mg PO QID x 5-7 days",
              "alternative": "Fosfomycin 3g PO single dose"
            },
            "pre_urologic_procedure": {
              "first_line": "Base on urine culture susceptibilities. Treat 1-2 days before procedure. Options: Ciprofloxacin 500mg PO BID OR TMP-SMX DS PO BID OR Cephalexin 500mg PO QID (if susceptible)",
              "duration": "1-2 days before procedure, continue 1-3 days after (total 3-5 days)"
            },
            "kidney_transplant": {
              "first_line": "Consult transplant ID. Typically: TMP-SMX DS PO BID OR Ciprofloxacin 500mg PO BID x 5-7 days (first 3-6 months post-transplant only)"
            },
            "do_not_treat": "Do NOT treat ASB in non-pregnant women, men (except pre-procedure), elderly, diabetics, catheterized patients, or spinal cord injury patients."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Amoxicillin 500mg PO TID OR Cephalexin 500mg PO QID OR Nitrofurantoin 100mg PO BID (pregnancy) OR Ciprofloxacin 500mg PO BID (pre-procedure)",
              "ESBL_producing": "Difficult. Consider fosfomycin 3g PO single dose (pregnancy) OR IV ertapenem (if severe or pre-procedure)",
              "Enterococcus": "Ampicillin 500mg PO QID OR Amoxicillin 500mg PO TID",
              "GBS_in_pregnancy": "Ampicillin 500mg PO QID x 5-7 days. NOTE: GBS bacteriuria = heavy colonization, requires intrapartum antibiotic prophylaxis (IAP) during labor."
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results.",
            "iv_to_po_switch": "Not applicable (oral therapy for ASB)"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "pregnancy": "5-7 days. Test of cure (repeat urine culture) 1-2 weeks after treatment.",
            "pre_urologic_procedure": "3-5 days total (1-2 days before + 1-3 days after procedure)",
            "kidney_transplant": "5-7 days (first 3-6 months post-transplant only)",
            "do_not_treat": "0 days for all other populations (no treatment indicated)"
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "elderly": "Do NOT treat ASB in elderly (including nursing home residents). Treatment does NOT reduce morbidity, mortality, or symptomatic UTI. May increase antibiotic resistance and adverse effects.",
            "catheterized_patients": "Do NOT treat ASB in catheterized patients. Nearly all catheterized patients have bacteriuria. Treatment does NOT prevent symptomatic CAUTI. Remove catheter if no longer needed.",
            "diabetics": "Do NOT treat ASB in diabetics. No evidence of benefit. May increase resistance.",
            "spinal_cord_injury": "Do NOT treat ASB in spinal cord injury patients. Treatment does NOT prevent symptomatic UTI and increases resistance.",
            "chronic_kidney_disease": "Do NOT treat ASB in CKD patients. No evidence of benefit.",
            "post_kidney_transplant": "Treat ASB only in first 3-6 months post-transplant. After 6 months, do NOT treat ASB.",
            "pre_procedure_screening": "Screen for ASB before urologic procedures with mucosal trauma (TURP, cystoscopy with biopsy, stone removal). Do NOT screen before clean procedures (cystoscopy without biopsy, urodynamics)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Confirm patient has symptoms before treating 'UTI'",
              "Do NOT treat ASB in non-pregnant, non-procedure patients",
              "Do NOT obtain urine cultures in asymptomatic patients",
              "Educate providers on when NOT to treat ASB",
              "Remove catheters if no longer needed (instead of treating ASB)"
            ],
            "avoid_unnecessary_treatment": "ASB is one of the most common causes of inappropriate antibiotic use. Do NOT treat ASB except in pregnancy, pre-urologic procedure, or early post-transplant. Pyuria alone is NOT an indication for treatment.",
            "patient_education": "Educate patients that bacteria in urine without symptoms is common and does NOT require antibiotics (except pregnancy). Cloudy or foul-smelling urine alone is NOT an indication for treatment.",
            "nursing_home_stewardship": "Implement protocols to avoid urine testing in asymptomatic nursing home residents. Use McGeer criteria for diagnosing UTI in long-term care (requires symptoms + positive culture)."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA Asymptomatic Bacteriuria Guidelines (2019)",
              "url": "https://www.idsociety.org/practice-guideline/asymptomatic-bacteriuria/"
            },
            {
              "label": "USPSTF Screening for ASB (2019)",
              "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/asymptomatic-bacteriuria-in-adults-screening"
            },
            {
              "label": "CDC Catheter-Associated UTI Prevention (2024)",
              "url": "https://www.cdc.gov/hai/ca_uti/uti.html"
            }
          ]
        }
      }
    },
    {
      "id": "renal-abscess",
      "name": "Renal & Perinephric Abscess",
      "synonyms": ["kidney abscess", "perinephric abscess", "intrarenal abscess"],
      "icd10": ["N15.1", "N15.9"],
      "severity": ["severe"],
      "shortDescription": "Localized collection of pus within the renal parenchyma (renal abscess) or in the space between kidney and Gerota's fascia (perinephric abscess)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Renal abscess: Localized collection of pus within the renal parenchyma. Perinephric abscess: Collection of pus in the perinephric space (between kidney capsule and Gerota's fascia). Both are serious complications of pyelonephritis or hematogenous seeding.",
            "clinical_presentation": "Fever, chills, flank pain, costovertebral angle tenderness, malaise. Symptoms often persist >5-7 days despite antibiotics for pyelonephritis. May have palpable flank mass. Sepsis in 20-30%.",
            "diagnostic_criteria": "Clinical symptoms + imaging (CT or ultrasound) showing fluid collection with rim enhancement. Blood or urine cultures may be positive.",
            "risk_factors": [
              "Diabetes mellitus (50-70% of cases)",
              "Urinary tract obstruction (stones, stricture)",
              "Recent pyelonephritis",
              "Immunosuppression",
              "IV drug use (hematogenous seeding)",
              "Polycystic kidney disease",
              "Recent urologic instrumentation"
            ],
            "red_flags": [
              "Septic shock",
              "Persistent fever >72 hours despite antibiotics for pyelonephritis",
              "Abscess >5cm (usually requires drainage)",
              "Gas-forming organisms (emphysematous pyelonephritis)",
              "Bilateral abscesses"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "Suspect renal/perinephric abscess if pyelonephritis not improving after 72 hours of appropriate antibiotics. Obtain imaging (CT preferred).",
            "essential_tests": [
              "CT abdomen/pelvis with IV contrast (GOLD STANDARD - shows abscess, size, location, gas)",
              "Blood cultures (2 sets) - Positive in 40-60%",
              "Urine culture with susceptibilities",
              "CBC, CMP (assess renal function, WBC, glucose)"
            ],
            "conditional_tests": [
              "Renal ultrasound: If CT contraindicated (pregnancy, contrast allergy). Less sensitive than CT.",
              "Abscess aspiration/drainage: For culture and susceptibilities (especially if blood/urine cultures negative)",
              "Chest X-ray: If concern for septic emboli (hematogenous seeding)"
            ],
            "imaging_findings": "CT: Hypodense fluid collection with rim enhancement. May see gas (emphysematous). Perinephric abscess extends beyond kidney capsule. Renal abscess confined to parenchyma.",
            "turnaround_time": "CT: Same day (urgent). Blood/urine cultures: 24-48 hours. Abscess culture: 24-48 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": {
              "ascending_infection": [
                "Escherichia coli (most common, 50-70%)",
                "Klebsiella pneumoniae",
                "Proteus mirabilis",
                "Enterococcus spp.",
                "Pseudomonas aeruginosa"
              ],
              "hematogenous_seeding": [
                "Staphylococcus aureus (MSSA or MRSA) - Especially in IV drug users",
                "Streptococcus spp."
              ]
            },
            "polymicrobial": "20-30% of cases are polymicrobial, especially if perinephric abscess.",
            "resistance_patterns": "High rates of ESBL (20-30%) and fluoroquinolone resistance (30-40%). MRSA if hematogenous seeding.",
            "anaerobes": "Rare, but consider if gas-forming abscess or recent GI surgery."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "ascending_infection": "Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (if ESBL risk or severe)",
              "hematogenous_seeding": "Vancomycin 15-20mg/kg IV q8-12h + Piperacillin-tazobactam 3.375g IV q6h (covers MRSA + Gram-negatives)",
              "iv_drug_user": "Vancomycin 15-20mg/kg IV q8-12h + Cefepime 2g IV q8h (covers MRSA + Pseudomonas)"
            },
            "alternatives": "Beta-lactam allergy: Aztreonam 2g IV q8h + vancomycin 15-20mg/kg IV q8-12h.",
            "avoid_list": "Avoid oral antibiotics initially. Avoid nitrofurantoin (inadequate tissue levels). Avoid monotherapy (high failure rate).",
            "source_control": "Drainage is MANDATORY for abscesses >3-5cm or if no improvement in 48-72h despite antibiotics. Antibiotics alone have high failure rate."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific": {
              "E_coli_susceptible": "Ceftriaxone 2g IV daily OR Ciprofloxacin 400mg IV q12h (if susceptible)",
              "ESBL_producing": "Meropenem 1g IV q8h OR Ertapenem 1g IV daily",
              "Pseudomonas_aeruginosa": "Cefepime 2g IV q8h OR Piperacillin-tazobactam 3.375g IV q6h OR Meropenem 1g IV q8h (based on susceptibility)",
              "MSSA": "Nafcillin 2g IV q4h OR Cefazolin 2g IV q8h",
              "MRSA": "Vancomycin 15-20mg/kg IV q8-12h OR Daptomycin 6-8mg/kg IV daily",
              "Enterococcus": "Ampicillin 2g IV q6h (if susceptible) OR Vancomycin 15-20mg/kg IV q8-12h (if VRE)"
            },
            "de_escalation": "Switch to narrow-spectrum agent based on culture results. Discontinue vancomycin if no MRSA.",
            "iv_to_po_switch": "Criteria: Afebrile >48-72h, abscess drained or resolving on imaging, tolerating PO, pathogen susceptible to oral agent with good bioavailability. Switch after 2-4 weeks of IV therapy."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "4-6 weeks total (IV + PO) - Prolonged duration needed for abscess eradication",
            "short_course": "4 weeks if abscess <3cm and drained, good response",
            "prolonged": "6-8 weeks if abscess >5cm, delayed drainage, or slow response. Consider 8-12 weeks if perinephric abscess or immunosuppressed.",
            "iv_duration": "2-4 weeks IV, then switch to PO if improving and abscess drained/resolving."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "drainage_indications": "MANDATORY drainage if: Abscess >3-5cm, no improvement in 48-72h despite antibiotics, gas-forming abscess, or septic shock. Options: Percutaneous drainage (CT or ultrasound-guided) OR surgical drainage (open or laparoscopic).",
            "percutaneous_drainage": "Preferred initial approach. CT or ultrasound-guided aspiration or catheter placement. Success rate: 70-90% if abscess <5cm.",
            "surgical_drainage": "Indicated if: Percutaneous drainage fails, abscess >10cm, multiloculated abscess, or need for nephrectomy (non-functioning kidney).",
            "diabetes_management": "Optimize glucose control (target <180mg/dL). Poor glycemic control associated with treatment failure.",
            "obstruction": "Urgent urology consult if obstructive uropathy (stone, stricture). Relieve obstruction (stent, nephrostomy) + drainage + antibiotics.",
            "immunosuppression": "Longer duration (6-8 weeks). Consider fungal coverage if prolonged broad-spectrum antibiotics or no improvement. Consult ID.",
            "renal_dose": "Adjust antibiotics for renal impairment (common with abscess)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review culture results (blood, urine, abscess) and de-escalate",
              "Ensure drainage performed if abscess >3-5cm or no improvement in 48-72h",
              "Switch IV to PO after 2-4 weeks if improving and abscess drained",
              "Repeat imaging at 2-4 weeks to assess abscess resolution",
              "Ensure total duration is 4-6 weeks (prolonged therapy needed)",
              "Discontinue vancomycin if no MRSA"
            ],
            "iv_to_po_opportunities": "Most patients can switch to PO after 2-4 weeks of IV therapy if afebrile, abscess drained/resolving, and pathogen susceptible to oral agent. Oral options: Ciprofloxacin, levofloxacin, TMP-SMX, linezolid (MRSA).",
            "source_control": "Antibiotics alone have high failure rate (30-50%). Drainage is MANDATORY for most abscesses. Do NOT delay drainage if indicated.",
            "follow_up_imaging": "Repeat CT or ultrasound at 2-4 weeks to confirm abscess resolution. If not resolving, consider repeat drainage or surgical intervention."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "EAU Guidelines on Urological Infections (2024)",
              "url": "https://uroweb.org/guidelines/urological-infections"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "IDSA Complicated UTI Guidelines (2010, updated 2019)",
              "url": "https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/"
            }
          ]
        }
      }
    }
  ]
}

